Introduction
Cytochromes P450 (CYP) enzymes are responsible for eliminating approximately 75% of marketed drugs, and pregnancy is known to alter P450-mediated hepatic drug metabolism. Results from clinical studies indicate that during pregnancy, elimination of drugs metabolized by CYP2A6, CYP3A4, CYP2D6, and CYP2C9 is increased, whereas elimination of the CYP1A2 and CYP2C19 substrate drugs is decreased (Hodge and Tracy, 2007) . Pregnancy is also accompanied by increases in plasma concentrations of multiple hormones including estrogen, progesterone and corticosteroids, and these hormones may be in part responsible for altered drug metabolism during pregnancy. For example, results from previous studies indicate that rising concentrations of estrogen and progesterone may lead to increased elimination of CYP2B6 and CYP3A4 substrate drugs during pregnancy (Koh et al., 2012; Choi et al., 2013; Papageorgiou et al., 2013) .
Prolactin (PRL), placental lactogen (PL) and growth hormone variant (GH-v) are peptide hormones belonging to the growth hormone family, and their plasma concentrations increase during pregnancy. For example, plasma concentration of PRL rises >10-fold during pregnancy as compared with the basal level in nonpregnant women. PL and GH-v are pregnancy-specific somatotropins produced from placenta. PL secretion rate is about 1.0 g/day at term, a rate considerably greater than that of any other peptide hormones (Handwerger and Freemark, 2000) . GH-v is the predominant growth hormone in the systemic circulation of pregnant women due to decreased pituitary production of native growth hormone during pregnancy. These peptide hormones share similar genetic, structural, binding and glucuronosyltransferase (Luquita et al., 1996) . However, significant inter-species differences in amino acid sequences and biological activities of PRL (Forsyth and Wallis, 2002; Ben-Jonathan et al., 2008) render extrapolation to humans difficult. GH-v was recently shown to have insignificant effects on the expression and activity of the major drug-metabolizing enzyme CYP3A4 in human hepatocytes (Papageorgiou et al., 2013) , but whether GH-v influences expression of other P450 isoforms is unclear.
The effects of PL on human P450 expression and activity are completely unknown.
The biological action of GH-v and PRL is initiated by hormone binding to the growth hormone receptor or the PRL receptor (PRLR), respectively, on cell membranes. Of these two membrane receptors, PL is known to bind preferentially to PRLR (Handwerger and Freemark, 2000) . The hormone binding to the receptor triggers activation (i.e., phosphorylation) of a number of signaling proteins, including signal transducers and activators of transcription (STAT). A previous study showed that STAT5a and STAT5b were activated by ovine PRL, mouse PL, and rat growth hormone in primary rat hepatocytes (Cao et al., 2001) .
In this study, we examined whether PRL, PL, and GH-v modulate expression and/or activity of HNF1α response element (5′-GGTTA ATATT TACCG GTTAA TGATT   ACCGG TTAATC TTTAA CGGTT AATTA TTAAC-3′) were cloned into pGL3 vector (Promega) proximal to the thymidine kinase-driven luc gene, and the resulting plasmid was named HNF1α RE-luc.
Cell Culture. HepG2 cells from the American Type Culture Collection (ATCC, Manassas, VA) were cultured in complete DMEM supplemented with 10% fetal bovine serum (Gemini, Woodland, CA), 2 mM L-glutamine, 100 U penicillin/mL, 100 μg streptomycin/mL, and 1% MEM nonessential amino acids.
HepaRG
TM cells were purchased from Biopredic international (Rennes, France) and maintained in 25 cm 2 culture flask in William's E medium supplemented with 10% FBS, 100 U penicillin/mL, 100 μg streptomycin/mL, 5 μg/mL insulin, 2 mM L-glutamine, and 50 μM hydrocortisone. Then, the cells were seeded onto 12-well plates at a density of 2x10 5 cells/mL and cultured for 14 days, after which the cells were used for experiments.
Primary Hepatocyte Culture. Freshly isolated human hepatocytes from female donors of age 18-50 years were obtained from Life Technologies (Pittsboro, NC), BD biosciences (San Jose, California), and Liver Tissue Cell Distribution System (Pittsburgh, PA). Briefly, human hepatocytes were shipped overnight in cold preservation media. Upon receipt, the media were replaced with serum-free Williams' E media (without phenol red) containing 0.1 μ M dexamethasone, 100 U penicillin/mL, 100 μ g streptomycin/mL, 15 mM HEPES, 2 mM L-glutamine, 5.5 μ g/mL transferrin, and 5 ng/mL sodium selenite. Cells were allowed to recover from shipping for 18 h at 37 °C in an atmosphere containing 5% CO 2 , and used for experiments on the next day. Mouse hepatocytes were isolated from the livers of CYP2E1-humanized mice as previously described (Swift and Brouwer, 2010) and cultured as described above for human hepatocytes.
This article has not been copyedited and formatted. The final version may differ from this version. Precursor RNA Analysis. RNA was prepared from hormone-treated cells and treated with DNase I.
The RNA was then reverse-transcribed using an intron 6-specific CYP2E1 primer (5′-ACACA TCCAT TGACC CATCC-3′), and qRT-PCR was performed using a primer set that can detect intron 5 and exon 6 of CYP2E1 (Life Technologies; Hs01666884_cn). As a loading control, precursor RNA level of GAPDH was used. To this end, an intron 6-specific GAPDH primer (5′-CGGCC ATCAC GCCAC AGTTT-3′) and a primer set that can detect exon 5 and intron 5 of GAPDH (Life Technologies; Hs00894322_cn)
were used for reverse-transcription and qRT-PCR, respectively. The fold change in the precursor RNA levels of CYP2E1 was determined after normalizing the gene expression levels to those of GAPDH (2 -∆∆Ct method).
Western Blot Analysis. Cell lysates were prepared from drug-treated human hepatocytes, and proteins (30 μg) were separated using 12% SDS-polyacrylamide gel electrophoresis and transfered onto a nitrocellulose membrane. Blots were blocked with 5% skim milk/Tris buffered saline containing 0.1% Tween 20 (TBST) for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against CYP2E1 or β -actin diluted according to the manufacturer's specifications in 1% skim milk/TBST.
The membranes were then washed in TBST before incubation with horseradish peroxidase-coupled anti- were grown for 24 h and treated with PL (6 μg/mL) or bicarbonate buffered saline (vehicle). On the next day, cells were harvested, and firefly and Renilla luciferase activities were measured using assay kits from Promega. Firefly luciferase activity was normalized to the Renilla luciferase activity.
Inhibition of Cell Signaling. Human hepatocytes were treated with PL or vehicle in the presence or absence of one of the following signaling inhibitors (1 μM): wortmannin, rapamycin, Ro 31-8220, U0126, and SB202190 for inhibition of PI3 kinase, p70 S6 kinase, PKC, MEK, and p38 MAPK, respectively.
After 72 h, cell lysates were collected and analyzed.
Statistical Analysis. Each experiment with primary human hepatocytes was conducted in triplicate, and data were expressed as mean ± standard deviation (S.D.). Statistical analysis for human hepatocyte experiments with different hormones was performed by two-way ANOVA, followed by posthoc Bonferroni test. For luciferase reporter assays, at least two independent experiments were performed in triplicate, and the Student's t-test was performed for statistically analysis. For cell signaling experiments, one-way ANOVA was performed, followed by posthoc Dunnett's test.
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Results
PL induces CYP2E1 expression. To determine the effects of PRL, PL and GH-v on the expression of major P450 enzymes, human hepatocytes were treated with PRL (150 ng/mL), PL (6 μg/mL), GH-v (20 ng/mL), or bicarbonate buffered saline (vehicle), and mRNA expression levels of CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4, and 3A5 were measured by qRT-PCR. The concentrations of hormones chosen for this study reflect the maternal serum levels during the third trimester of pregnancy (MacDonald et al., 1980; Kletzky et al., 1985) . The concentrations of PRL and PL in the media did not decrease more than 10% over the treatment period (ELISA assays; data not shown). Furthermore, the treatment with PRL, PL, or GH-v did not cause cytotoxicity to the hepatocytes (LDH assays; data not shown). PRL and GH-v exhibited either no effect or small and variable effects on P450 expression (supplemental Figure 1) ; in a single batch of human hepatocytes, PRL enhanced CYP2E1 by 1.6-fold while GH-v enhanced CYP2D6 and CYP3A4 by 2.3-and 2.4-fold, respectively. On the other hand, PL significantly induced the expression level of CYP3A5 (1.5-to 4.5-fold induction) in all human hepatocytes. Also, PL significantly enhanced CYP2E1 expression (2.8-to 15.3-fold) in all hepatocytes whereas its effects on the remaining P450 expression were insignificant or variable ( Figure 1A ). CYP2E1
induction by PL was most prominent in hepatocytes #4. Of note, only in the hepatocytes #4, PL inhibited mRNA expression of CYP2A6, CYP2C19, and CYP3A4, demonstrating significant donor-to-donor variability as typically seen in studies using primary hepatocytes (McGinnity et al., 2009) . A similar increase in CYP2E1 expression by PL was also shown in HepaRG cells ( Figure 1B) ; however, the magnitude of CYP2E1 induction by PL in HepaRG was lower than that in human hepatocytes for unknown reasons. Treatment of mouse hepatocytes isolated from CYP2E1-humanized mice with human PL did not affect CYP2E1 expression (data not shown), indicating the need to use appropriate experimental systems in studying the physiology of PL.
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To determine whether the increased CYP2E1 mRNA levels led to corresponding increases in protein expression and enzymatic activity, protein and metabolic activity of CYP2E1 were analyzed in the human hepatocytes by using western blot and the CYP2E1 probe drug chlorzoxazone, respectively. The results
showed that PL increased CYP2E1 protein ( Figure 2B ). The formation of 6-hydroxychlorzoxazone was increased significantly in the hepatocytes pre-treated with PL at most of the time points ( Figure 2C ).
Taken together, these results indicate that at concentrations reached during pregnancy, PL increases CYP2E1 expression.
To determine whether CYP2E1 induction by PL occurs at the transcriptional level, the effects of PL on the level of CYP2E1 precursor RNA (an immature mRNA before processing) were examined in human hepatocytes from a different donor. The hepatocytes were treated with PL or vehicle, RNA isolated, and the level of precursor RNA measured by qRT-PCR using a primer set that can detect the intron regions of CYP2E1. PL significantly increased the level of CYP2E1 precursor RNA as compared with vehicle treatment, accompanied by a similar extent of increase in CYP2E1 mRNA level ( Figure 2D ).
Together, these results indicate that CYP2E1 induction by PL likely occurs at the transcriptional level. chosen because the expression levels of hepatic genes (likely including DCoH) in these cells are comparable to those in primary human hepatocytes (Lubberstedt et al., 2011) . In the vehicle-treated cells, overexpression of HNF1α significantly increased the luciferase activity, indicating that components for proper HNF1α actions are present and functional in HepaRG cells ( Figure 3C ). However, PL did not induce HNF1α RE-luc activity in the cells (Figure 3C ), indicating a lack of PL effects on HNF1α activity.
HNF1α is not involved in
Together, these results indicate that PL does not affect the expression or activity of HNF1α, and that did not activate any of the STATs ( Figure 3E ). Taken together, these results indicate that STAT signaling is likely not responsible for CYP2E1 induction by PL.
PI3 kinase plays a key role in CYP2E1 induction by PL. In primary rat hepatocytes, insulin was shown to modulate CYP2E1 mRNA expression via activation of PI3 kinase and p70 S6 kinase signaling pathways (Woodcroft et al., 2002) . To examine whether one or more intracellular signaling pathways mediating insulin reaction are involved in CYP2E1 induction by PL, human hepatocytes were treated with vehicle or PL for 72 h in the presence of signaling inhibitors (wortmannin for PI3 kinase, rapamycin for p70 S6 kinase, Ro 31-8220 for PKC, U0126 for MEK, and SB202190 for p38 MAPK inhibition), and CYP2E1 mRNA levels were determined by qRT-PCR. In human hepatocytes, the enhanced CYP2E1 expression by PL was significantly attenuated by wortmannin but not by any of the remaining inhibitors ( Figure 4A ), suggesting significant roles of PI3 kinase in mediating CYP2E1 induction by PL.
AKT, a serine/threonine specific protein kinase, is known to be a key mediator for PI3 kinase signaling pathway (Fayard et al., 2010) . To further verify the involvement of PI3K in PL action, whether PL activates AKT was examined. Human hepatocytes or HepaRG cells were treated with vehicle or PL for 30 min, and activated (i.e., phosphorylated) AKT was detected by western blot. The result showed that the level of phosphorylated AKT was increased upon treatment with PL ( Figure 4B ). Wortmannin abolished AKT phosphorylation, verifying that AKT is a downstream effector of PI3 kinase. Together, these data indicate that PL activates PI3 kinase/AKT signaling pathway.
CYP2E1 expression is not increased in CYP2E1-humanized mice during pregnancy. To determine
whether PL effects on CYP2E1 lead to enhanced CYP2E1 expression during pregnancy, a CYP2E1-humanized mouse line was used. The genome of CYP2E1-humanized mice harbors the complete human CYP2E1 gene along with 2.7-kb of upstream region of the CYP2E1 gene (Cheung et al., 2005) . Liver samples were collected from the mice at pre-pregnancy, 7 or 17 days of pregnancy, and 30 days 
Discussion
In this study, we examined the effects of PRL, PL, and GH-v on expression of hepatic drugmetabolizing enzymes in human hepatocytes and investigated the underlying regulatory mechanisms.
The results demonstrated that PL enhances CYP2E1 expression in primary human hepatocytes, in part by activation of PI3 kinase signaling pathways.
CYP2E1 contributes to a small portion (i.e., 5-10%) of overall P450-mediated metabolism, but the significance of this enzyme cannot be overlooked, due to its toxicological role in the metabolic activation of many carcinogenic and toxic chemicals as well as the production of reactive oxygen species (Lu and Cederbaum, 2008) . Potentially because of its physiological significance, CYP2E1 expression is highly regulated. Several regulatory mechanisms for CYP2E1 expression have been reported, including transcriptional regulation (Umeno et al., 1988; Vieira et al., 1996) , post-transcriptional mechanisms (Song et al., 1987; Yang and Cederbaum, 1997; Khalighi et al., 1999) , and post-translational protein stabilization (Song et al., 1989) . Our results showed that in human hepatocytes, PL increases the precursor RNA levels of CYP2E1, suggesting that PL induces CYP2E1 via transcriptional activation of the gene.
It was previously demonstrated that HNF1α is a transcription activator of CYP2E1 through direct binding to the promoter (Liu and Gonzalez, 1995; Cheung et al., 2003) . Of note, the transcriptional activity of HNF1α can be modulated without any changes in HNF1α expression, by post-translational modification of HNF1α (Lim et al., 2002) or by altered expression of its cofactor DCoH (Mendel et al., 1991 The results from this study demonstrate that PL enhances CYP2E1 expression by activating PI3 kinase in human hepatocytes. Of interest, a previous study has shown that activation of PI3 kinase by insulin leads to repressed CYP2E1 expression (Woodcroft et al., 2002) whereas in this study, activation of PI3 kinase by PL led to enhanced CYP2E1 expression. Although detailed underlying mechanisms for the differential actions of PL and insulin warrant comparative studies, this seemingly conflicting data may be explained by the complexity of intracellular signaling pathways. For example, insulin is known to activate PI3 kinase and the downstream AKT signaling, but transgenic mice with decreased PI3 kinase function (via liver-specific deletion of a major regulatory subunit of PI3 kinase) exhibit increased AKT activation (Taniguchi et al., 2006) , suggesting that insulin may modulate other signaling pathways, the net result of which is AKT activation. Similarly, it appears plausible that PL activates a distinct set of multiple intracellular signaling pathways (including PI3 kinase), a net result of which is the CYP2E1 induction. The additional signaling pathways activated by PL remain to be identified.
Humans and mice have shown significant inter-species differences in the directional changes in P450-mediated drug metabolism during pregnancy. For example, CYP2D6-mediated drug metabolism increases during pregnancy in humans (Hodge and Tracy, 2007) whereas expression of CYP2D homologs decreases in mice (Koh et al., 2011) . This is potentially due to DNA sequence differences in the upstream regulatory region of P450 genes between humans and mice. In this regard, CYP-humanized mice whose that pregnancy enhances CYP2E1 expression. In CYP2E1-humanized mice, however, the CYP2E1 expression was decreased during pregnancy. Inter-species differences in hormone physiology may have contributed to the finding. For example, while the human placenta produces one form of PL, the mouse placenta produces two different forms of PL (mPL1 and mPL2) whose amino acid sequences share less than 50% homology with those of human PL. Whether pregnancy indeed affects CYP2E1 expression and activity remains to be determined in humans.
Many of CYP2E1 substrates are known to produce toxic metabolites. For example, CYP2E1 metabolizes isoniazid to acetylhydrazine that triggers hepatitis (Yue et al., 2004) . Of interest, pregnant women are four-times more likely to develop isoniazid-mediated hepatitis than nonpregnant women are (Kawamoto et al., 1999) , suggesting that expression and activity of CYP2E1 may increase during pregnancy. CYP2E1 plays a major role in metabolizing acetaminophen (a commonly used analgesic during pregnancy) to N-acetyl-p-benzoquinone, the toxic metabolite causing fatal liver injury (Lee et al., 1996) . Of note, a recent study demonstrated that acetaminophen elimination to oxidative metabolites was significantly increased in women at delivery, compared to that in postpartum women, suggesting clinically relevant increase in CYP2E1 expression and/or activity during pregnancy (Kulo et al., 2013) .
Taken together, caution should be advised when acetaminophen is prescribed to pregnant women.
In summary, the present study showed that PL increases CYP2E1 expression and activity in human hepatocytes in part by PI3 kinase signaling pathway. The results underscore significant interspecies differences in PL physiology between humans and mice. This represents the first report of human PL affecting hepatic functions and should shed light on physiological and molecular basis of human PL action.
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